Copyright © 1994 by the European Society of Cardiology.
© 1994 The European Society of Cardiology
Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction
Results from the Captopril And Thrombolysis Study (CATS)
*Department of Cardiology, St. Antonius Hospital Nieuwegein
Department of Clinical Pharmacology, University of Groningen Groningen
Department of Cardiology, Catharina Hospital Eindhoven
Department of Cardiology, Free University Hospital Amsterdam
¶Department of Cardiology, Ignatius Hospital Breda, NL
Received 5 November 1993; revised 18 February 1994; .
Correspondence J Herre Kingma, Captopril and Thrombolysis Study (CATS) coordinaton centre, St,Antonius Hospital, P.O Box 2500, 3430 EM Nieuwegein, The Netherlands. (NL).
Abstract
The study was designed to examine the safety and efficacy of acute interventional use of captopril on left ventricular volumes, ventricular arrhythmias and neurohormones during thrombolysis in patients with a first anterior myocardial infarction, within 6 h of onset of symptoms.
Left ventricular dysfunction and prognosis after myocardial infarction can be improved by angiotensin converting enzyme inhibition started after the ischaemic phase. Experimental evidence suggests that intervention during thrombolysis may lead to even further benefit.
In a randomized, double-blind placebo-controlled trial, 298 patients with a first anterior myocardial infarction, eligible for thrombolytic therapy were treated with captopril 6.25 mg or placebo, started immediately upon streptokinase infusion and titrated to 2.5 mg t.i.d. The efficacy of captopril by an intention-to-treat-analysis to reduce left ventricular volumes, ventricular arrhythmias, neurohumoral activation and enzymatic infarct size was measured.
During dose titration, mean blood pressure and heart rate were similar in both groups. However, hypotension after the first dose was reported in 18 patients on placebo and 31 patients on captopril (P<0.05). At discharge, 80% of patients were on study medication. Left ventricular volumes were significantly increased in both groups at 3 months, but they tended to be lower in the captopril group; however, the differences were not statistically significant. The incidence of accelerated idioventricular rhythm and non-sustained ventricular tachycardia in captopril patients was lower than in placebo patients (P<0.05), parallelled by transiently lower norepinephrine levels (P<0.05) upon thrombolysis. In addition, enzymatic infarct size was smaller in captopril patients, especially in larger infarcts (P<0.05), and a 34% (95% confidence interval; 0–56%) lower incidence of heart failure during 3 months follow-up was reported in the captopril group.
Captopril is well tolerated, although hypotension after the first dose was more common than in patients on placebo. In agreement with experimental studies, captopril reduces repetitive ventricular arrhythmias and catecholamine levels in the acute thrombolytic phase of myocardial infarction. Although left ventricular volumes were not significantly smaller in captopril patients, in the chronic phase, these patients showed a reduced incidence of heart failure.
This study was carried out under auspices of the Interuniversity Institute of the Netherlands (ICIN) and the Working Group of Cardiovascular Research the Netherlands (WCN). Financial support was received from Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, N.J., U.S.A.
Key Words: Captopril • thrombolysis • myocardial infarction • left ventricular volumes • ventricular arrhythmias • neurohumoral activation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Kloner and D. S. Cannom Uncertainty on the Use of Aldosterone Antagonists for Primary Therapy for Sudden Cardiac Death in the Setting of Implanted Devices Circulation, June 12, 2007; 115(23): 2983 - 2989. [Full Text] [PDF]
|
|
|
|
 |
|
 J. McMurray, L. Kober, M. Robertson, H. Dargie, W. Colucci, J. Lopez-Sendon, W. Remme, D. N. Sharpe, and I. Ford Antiarrhythmic effect of carvedilol after acute myocardial infarction: Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial J. Am. Coll. Cardiol., February 15, 2005; 45(4): 525 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Coletta, A Sestili, F Seccareccia, R Rambaldi, R Ricci, A Galati, R Bigi, N Aspromonte, M Renzi, and V Ceci Influence of contractile reserve and inducible ischaemia on left ventricular remodelling after acute myocardial infarction Heart, October 1, 2003; 89(10): 1138 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E van der Elst, H. Buurma, M. L Bouvy, and A. de Boer Drug Therapy for Prevention of Recurrent Myocardial Infarction Ann. Pharmacother., October 1, 2003; 37(10): 1465 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J E Otterstad Measuring left ventricular volume and ejection fraction with the biplane Simpson's method Heart, December 1, 2002; 88(6): 559 - 560. [Full Text] [PDF]
|
|
|
|
 |
|
 P.-J. de Kam, A. A. Voors, J. Brouwer, M. St John Sutton, and W. H. van Gilst Approaches to statistical analysis of repeated echocardiographic measurements after myocardial infarction and its relation to heart failure: Application of a random-effects model Eur J Heart Fail, June 1, 2002; 4(3): 277 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Nijland, O Kamp, P M J Verhorst, W G de Voogt, H G Bosch, and C A Visser Myocardial viability: impact on left ventricular dilatation after acute myocardial infarction Heart, January 1, 2002; 87(1): 17 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. de Kam, A. A. Voors, M. P. van den Berg, D. J. van Veldhuisen, J. Brouwer, H. J. G. M. Crijns, C. Borghi, E. Ambrosioni, J. S. Hochman, T. H. LeJemtel, et al. Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: Results of a meta-analysis of 845 patients J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2047 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Spinar, J. Vitovec, L. Spinarova, L. Pluhacek, B. Fischerova, and J. Toman A comparison of intervention with losartan or captopril in acute myocardial infarction Eur J Heart Fail, March 1, 2000; 2(1): 91 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Domanski, D. V. Exner, C. B. Borkowf, N. L. Geller, Y. Rosenberg, and M. A. Pfeffer Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials J. Am. Coll. Cardiol., March 1, 1999; 33(3): 598 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfeffer ACE Inhibitors in Acute Myocardial Infarction : Patient Selection and Timing Circulation, June 9, 1998; 97(22): 2192 - 2194. [Full Text] [PDF]
|
|
|
|
|
|
Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial Infarction : Systematic Overview of Individual Data From 100 000 Patients in Randomized Trials Circulation, June 9, 1998; 97(22): 2202 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. St. J. Sutton, M. A. Pfeffer, L. Moye, T. Plappert, J. L. Rouleau, G. Lamas, J. Rouleau, J. O. Parker, M. O. Arnold, B. Sussex, et al. Cardiovascular Death and Left Ventricular Remodeling Two Years After Myocardial Infarction : Baseline Predictors and Impact of Long-term Use of Captopril: Information From the Survival and Ventricular Enlargement (SAVE) Trial Circulation, November 18, 1997; 96(10): 3294 - 3299. [Abstract] [Full Text]
|
|
|
|
|
|
L. Bolognese, G. Cerisano, P. Buonamici, A. Santini, G. M. Santoro, D. Antoniucci, and P. F. Fazzini Influence of Infarct-Zone Viability on Left Ventricular Remodeling After Acute Myocardial Infarction Circulation, November 18, 1997; 96(10): 3353 - 3359. [Abstract] [Full Text]
|
|
|
|
|
|
M. Oosterga, A. A. Voors, P.-J. de Kam, H. Schunkert, Y. M. Pinto, J. H. Kingma, and W. H. van Gilst Plasma Angiotensin-Converting Enzyme Activity and Left Ventricular Dilation After Myocardial Infarction Circulation, June 17, 1997; 95(12): 2607 - 2609. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Pfeffer, S. C. Greaves, J. M. O. Arnold, R. J. Glynn, F. S. LaMotte, R. T. Lee, F. J. Menapace Jr, E. Rapaport, P. M. Ridker, J.-L. Rouleau, et al. Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction : The Healing and Early Afterload Reducing Therapy Trial Circulation, June 17, 1997; 95(12): 2643 - 2651. [Abstract] [Full Text]
|
|
|
|
|
|
R. Latini, A. P. Maggioni, M. Flather, P. Sleight, and G. Tognoni ACE Inhibitor Use in Patients With Myocardial Infarction : Summary of Evidence From Clinical Trials Circulation, November 15, 1995; 92(10): 3132 - 3137. [Full Text]
|
|
|
|
|
|
J.-H. E. Dambrink, A. SippensGroenewegen, W. H. van Gilst, K. H. Peels, C. A. Grimbergen, and J. H. Kingma Association of Left Ventricular Remodeling and Nonuniform Electrical Recovery Expressed by Nondipolar QRST Integral Map Patterns in Survivors of a First Anterior Myocardial Infarction Circulation, August 1, 1995; 92(3): 300 - 310. [Abstract] [Full Text]
|
|